Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Bietti's Crystalline Dystrophy Clinical Trial

Official title:

An Exploratory Clinical Study on Single Subretinal Injection of ZVS101e (rAAV2/8-hCYP4V2) Into Eyes With Bietti's Crystalline Dystrophy (BCD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05714904
• Other study ID #: ZVS101e-01
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 23, 2022
• Est. completion date: March 31, 2025

Study information

• Verified date: February 2023
• Source: Peking University Third Hospital
• Contact: Hongliang Dou, MD
• Phone: 010-82266563
• Email: douhongliang3736[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and tolerability of an adeno-associated virus vector expressing CYP4V2 in patients with Bietti's crystalline dystrophy (BCD).

Description:

This is a single-arm, open-label, and single-center study of ZVS101e in patients with BCD. A total of 6 participants will be enrolled. A retinal surgeon will administer the vector by subretinal injection. Safety, efficacy and vector shedding characteristics of ZVS101e are then measured over 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6
• Est. completion date: March 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willingness to adhere to protocol as evidenced by written informed consent;

2. Patients with clinical diagnosis of Bietti's crystalline dystrophy (BCD) (age = 18 years) (the age is based on the time of signing the informed consent form);

3. Genetic test confirmed to carry two pathogenic variants of CYP4V2 and carry no pathogenic mutations of other ophthalmic genetic diseases;

4. Agree to use reliable barrier contraception for 2 year after administration of ZVS101e;

5. The study eye must meet the following requirements: BCVA between 2.3 LogMAR and 0.5 LogMAR (including 2.3 LogMAR and 0.5 LogMAR); No refractive medium turbidity that affects fundus examination; Visible photoreceptor (outer nuclear) layer on a standard optical coherence tomography (OCT) scan.

Exclusion Criteria:

1. Lack of sufficient viable retinal cell. Specifically, if indirect ophthalmoscopy reveals less than I disc area of retina which is not involved by complete retinal degeneration, these eyes will be excluded. In addition, in eyes where OCT scans of sufficient quality can be obtained, areas of retina with thickness measurements less than 100 µm, or absence of neural retina, will not be targeted for delivery of AAV2-hCYP4V2;

2. Existing or pre-existing of choroidal neovascular (CNV) lesions that were secondary to BCD, or other eye conditions interfering with the surgery or the interpretation of the clinical endpoint, in the investigators' opinion;

3. The study eye has been treated with other drugs within 3 months that could affect the evaluation of the investigational drug (such as ranibizumab, bevacizumab, aflibercept, conbercept);

4. The study eye has been treated with the following intraocular procedures: retinal detachment surgery, vitrectomy;

5. Pre-existing eye conditions that the investigator evaluates could interfere with ocular evaluation, preclude surgery, interfere with interpretation of study endpoints or surgical complications (such as glaucoma, high refractive error, diabetes retinopathy or retinal vasculitis );

6. Currently taking or may require systemic medications that can cause ocular toxicity, such as psoralen, risedronate, or tamoxifen;

7. Patient with allergic constitution (such as those allergic to two or more drugs and food);

8. Those with the following laboratory abnormalities which are clinically significant:

Liver function: chronic liver disease, ALT increased >3 times the upper limit of normal; With uncontrolled hypertension, mean systolic blood pressure = 160 mmHg or mean diastolic blood pressure = 100 mmHg; With uncontrolled diabetes, HbA1c>10%; Patients with abnormal coagulation function (prothrombin time = upper limit of normal (3 seconds' longer), activated partial thromboplastin time = upper limit of normal (10 seconds' longer)); Serum virology test: Active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab) or syphilis antibody positive; Abnormality of tumor markers (alpha fetoprotein, carcinoembryonic antigen, CA125 carbohydrate antigen, CA153 carbohydrate antigen, CA199 carbohydrate antigen)

9. Having any past or present medical history that may affect the safety of the trial or the in vivo process of the drug, especially the medical history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, pulmonary, neurological, hematological, oncologic, immunological or metabolic disorders and others that are thought clinically significant by the investigator, such as diabetes, severe cardiac failure (New York Heart Association Class III and IV);

10. Participation in any medicine or medical device clinical trials within 3 months prior to enrollment;

11. Neutralizing antibodies to rAAV> 1:1000 by immunologic test;

12. For females in pregnancy or lactation period;

13. Any other conditions which leads the investigator to determine the participant is unsuitable for this study.

Related Conditions & MeSH terms

• Bietti's Crystalline Dystrophy
• Corneal Dystrophies, Hereditary
• Retinal Diseases

Intervention

Drug:
• ZVS101e
ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Jia R, Meng X, Chen S, Zhang F, Du J, Liu X, Yang L. AAV-mediated gene-replacement therapy restores viability of BCD patient iPSC derived RPE cells and vision of Cyp4v3 knockout mice. Hum Mol Genet. 2023 Jan 1;32(1):122-138. doi: 10.1093/hmg/ddac181. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of ocular and systemic adverse events (AEs) after ZVS101e treatment.	An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment.	Baseline up to Week 52
Primary	Incidence of ocular and systemic serious adverse events (SAEs) after ZVS101e treatment.	A serious adverse event (SAE) is any untoward medical occurrence at any dose that leading to the following: Results in death; Life-threatening, refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe; Significant or permanent disability/incapacity, where disability refers to a serious disruption and damage of a person's ability to perform normal life functions; Requires inpatient hospitalization or prolongation of existing hospitalization; Congenital anomaly or birth defect; Other medically important events.	Baseline up to Week 52
Primary	Type and severity of ocular and systemic AEs and SAEs after ZVS101e treatment.	Safety as the primary endpoint will be assessed by best-corrected visual acuity (BCVA), slit-lamp examination, ophthalmoscopy, fundus photography, intraocular pressure (IOP), optical coherence tomography (OCT), laboratory tests, vital signs, physical examinations, electrocardiogram (ECG), immunopathology and biodistribution of ZVS101e.	Baseline up to Week 52
Secondary	Mean change from baseline in BCVA after ZVS101e treatment;	BCVA of both eyes will be assessed using the early treatment of diabetic retinopathy study (ETDRS) chart.	Baseline up to Week 52
Secondary	Change from Baseline in visual field	Visual field will be assessed by Humphrey perimetry.	Baseline up to Week 52
Secondary	Change from Baseline in contrast sensitivity	Change from baseline in contrast sensitivity will be measured using the CSV-1000E instrument.	Baseline up to Week 52
Secondary	Change from Baseline in color vision	Subjects' color vision was classified and graded by having them identify the pictures within Color Vision Examination Plates.	Baseline up to Week 52
Secondary	Change from Baseline in retinal thickness	Retinal thickness will be assessed for both eyes using OCT.	Baseline up to Week 52
Secondary	Change from Baseline in NEI VFQ-25 total score	National eye institute 25-item visual function questionnaire (NEI VFQ-25) consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively.	Baseline up to Week 52
Secondary	Change from Baseline in multi-luminance mobility test (MLMT)	MLMT was assessed using both eyes at 1 or more of 7 levels of illumination, ranging from 400 lux (a brightly lit office) to 1 lux (a moonless summer night).	Baseline up to Week 52
Secondary	Change from Baseline in fundus autofluorescence (FAF).	FAF is a noninvasive test to explore the health and metabolic status of retinal pigment epithelial cell/photoreceptor complex.	Baseline up to Week 52
Secondary	Change from Baseline in mfERG	The measurement will be performed based on the standards of international society for clinical electrophysiology of vision (ISCEV).	Baseline up to Week 52
Secondary	Incidence of ocular and systemic AEs after ZVS101e treatment.	An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment.	Week 53 to Week 104
Secondary	Incidence of ocular and systemic SAEs after ZVS101e treatment.	A serious adverse event (SAE) is any untoward medical occurrence at any dose that leading to the following: Results in death; Life-threatening, refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe; Significant or permanent disability/incapacity, where disability refers to a serious disruption and damage of a person's ability to perform normal life functions; Requires inpatient hospitalization or prolongation of existing hospitalization; Congenital anomaly or birth defect; Other medically important events.	Week 53 to Week 104
Secondary	Type and severity of ocular and systemic AEs and SAEs after ZVS101e treatment.	Safety will be assessed by best-corrected visual acuity (BCVA), slit-lamp examination, ophthalmoscopy, fundus photography, intraocular pressure (IOP), optical coherence tomography (OCT), laboratory tests, vital signs, physical examinations, electrocardiogram (ECG), immunopathology and biodistribution of ZVS101e.	Week 53 to Week 104